Biocon Ltd’s share price fell 4.86 per cent on January 27, 2025, hitting a day’s low of Rs 369.40 on the NSE, while the NIFTY ...
As the US remains the top market for the Indian pharmaceutical industry, experts in India are now expecting opportunities for ...
US Ambassador to India, Eric Garcetti on Friday at the inauguration ceremony of US Consulate office in Bengaluru said that ...
Biocon’s shares surged over 7% on January 14, 2025, after HSBC upgraded its rating to ’Buy’ with a target price of ₹430, ...
With an increased confidence in the company’s prospects, HSBC raised its earnings estimates for Biocon, projecting ...
Biocon Ltd shares rose 4.7% after HSBC upgraded its rating to "buy" and raised the target price to Rs 430. The upgrade ...
The stock has gained 9.66% in the last month, 7.99% over the past six months, and an impressive 37.98% in the last year.
HSBC expects an operational turnaround for Biocon, driven by major biosimilar launches and a rebound in generics sales. The ...
Brokerages have turned bullish over Biocon's growth prospects after the US FDA clearance of the drugmaker's Malaysia unit ...
According to reports, HSBC said that Biocon is well-placed for an operational turnaround, driven by key biosimilar launches ...
Biocon Ltd. will be in focus on Monday, January 13, after the Biocon Biologics' insulin facility in Johor Bahru was classified as a "Voluntary Action Indicated" (VAI) by the USFDA. The facility was ...
Shares of Biocon Ltd surged as much as 5 per cent during the trading session on Monday after the United States Food and Drug Administration (USFDA) cleared the Malaysia unit, ending regulatory ...